MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL. The posters will be available following the embargo at https://MilestonePharma.com.
| Poster Presentation Title: | Characterizing Paroxysmal Supraventricular Tachycardia Episodes by Patient-Perceived Episode Duration, Symptoms, and Severity: Longitudinal Patient-Reported Outcomes (Encore) | ||
| Presenter: | Richard L. Sherwood, MD | ||
| Date and time: | April 18, 5:30-6:30pm EST | ||
| Poster Presentation Title: | Assessing the Real-World Impact of Paroxysmal Supraventricular Tachycardia on Quality of Life: A Longitudinal Study With a Focus on Anxiety Burden | ||
| Presenter: | Kathryn A. Wood, PhD, RN, FAHA, FAAN | ||
| Date and time: | April 18, 5:30-6:30pm EST | ||
| Poster Presentation Title: | Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Atrial Fibrillation: Phase 2 ReVeRA-201 (Encore) | ||
| Presenter: | James Nunez, PharmD | ||
| Date and time: | April 18, 5:30-6:30pm EST |
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications, kfox@milestonepharma.com
Investor Relations
Chris Calabrese, ccalabrese@lifesciadvisors.com
Kevin Gardner, kgardner@lifesciadvisors.com
| Last Trade: | US$1.28 |
| Daily Change: | 0.02 1.59 |
| Daily Volume: | 1,454,062 |
| Market Cap: | US$68.260M |
March 28, 2025 March 20, 2025 March 13, 2025 February 27, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
